Post-Transplant cyclophosphamide is associated with increase in Non-CMV Herpesvirus infections in Acute leukemia and MDS patients

Allogeneic hematopoietic cell transplantation (HCT) provides a curative potential for several hematologic malignancies. There has been a considerable increase in the number of partially matched (haploidentical) transplants performed globally 1. Traditionally, haploidentical transplants were associated with substantial bidirectional alloreactivity, which often resulted in graft failure or severe graft versus host disease (GVHD). However, the use of post-transplant cyclophosphamide (PTCy) in the haploidentical platform has resulted in improved GVHD rates and comparable overall outcomes to fully matched-donor transplants; thus, the PTCy platform is increasingly applied in the matched donor setting2.

Source: Biology of Blood and Marrow Transplantation - September 26, 2021 Category: Hematology Authors: Anurag Singh, Christopher E. Dandoy, Min Chen, Soyoung Kim, Carolyn M. Mulroney, Mohamed A. Kharfan-Dabaja, Siddhartha Ganguly, Richard T. Maziarz, Christopher G. Kanakry, Jennifer A. Kanakry, Sagar S. Patel, Joshua A. Hill, Satiro De Oliveira, Randy Tapl Source Type: research